213 related articles for article (PubMed ID: 12893208)
1. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus.
Wang L; Felix JC; Lee JL; Tan PY; Tourgeman DE; O'Meara AT; Amezcua CA
Gynecol Oncol; 2003 Aug; 90(2):402-6. PubMed ID: 12893208
[TBL] [Abstract][Full Text] [Related]
2. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
[TBL] [Abstract][Full Text] [Related]
3. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary.
Klein WM; Kurman RJ
Int J Gynecol Pathol; 2003 Apr; 22(2):181-4. PubMed ID: 12649674
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
5. C-kit protein expression in uterine and ovarian mesenchymal tumours.
Erdogan G; Bassorgun CI; Pestereli HE; Simsek T; Karaveli S
APMIS; 2007 Mar; 115(3):204-9. PubMed ID: 17367465
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series.
Leath CA; Straughn JM; Conner MG; Barnes MN; Alvarez RD; Partridge EE; Huh WK
J Reprod Med; 2004 Feb; 49(2):71-5. PubMed ID: 15018431
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies.
Oliva E; Young RH; Amin MB; Clement PB
Am J Surg Pathol; 2002 Apr; 26(4):403-12. PubMed ID: 11914617
[TBL] [Abstract][Full Text] [Related]
8. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Belda MALF; Averous G; Leroux A; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
Gynecol Oncol; 2022 Nov; 167(2):373-389. PubMed ID: 36114030
[TBL] [Abstract][Full Text] [Related]
9. C-kit expression in uterine leiomyosarcomas: an immunocytochemical study of 29 cases of malignant smooth muscle tumors of the uterus.
Raspollini MR; Villanucci A; Amunni G; Paglierani M; Taddei A; Taddei GL
J Chemother; 2003 Feb; 15(1):81-4. PubMed ID: 12678420
[TBL] [Abstract][Full Text] [Related]
10. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression.
Geller MA; Argenta P; Bradley W; Dusenbery KE; Brooker D; Downs LS; Judson PL; Carson LF; Boente MP
Gynecol Oncol; 2004 Dec; 95(3):632-6. PubMed ID: 15581975
[TBL] [Abstract][Full Text] [Related]
11. The protooncogene c-KIT is expressed in leiomyosarcomas of the uterus.
Raspollini MR; Paglierani M; Taddei GL; Villanucci A; Amunni G; Taddei A
Gynecol Oncol; 2004 Jun; 93(3):718. PubMed ID: 15196872
[No Abstract] [Full Text] [Related]
12. BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology.
Chiang S; Lee CH; Stewart CJR; Oliva E; Hoang LN; Ali RH; Hensley ML; Arias-Stella JA; Frosina D; Jungbluth AA; Benayed R; Ladanyi M; Hameed M; Wang L; Kao YC; Antonescu CR; Soslow RA
Mod Pathol; 2017 Sep; 30(9):1251-1261. PubMed ID: 28621321
[TBL] [Abstract][Full Text] [Related]
13. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment.
Raspollini MR; Amunni G; Villanucci A; Pinzani P; Simi L; Paglierani M; Taddei GL
Clin Cancer Res; 2004 May; 10(10):3500-3. PubMed ID: 15161707
[TBL] [Abstract][Full Text] [Related]
14. Uterine sarcomas: a review.
D'Angelo E; Prat J
Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas.
Caudell JJ; Deavers MT; Slomovitz BM; Lu KH; Broaddus RR; Gershenson DM; Ramondetta LM
Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):167-70. PubMed ID: 15894930
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas.
Jeffers MD; Richmond JA; Macaulay EM
Mod Pathol; 1995 Sep; 8(7):701-4. PubMed ID: 8539225
[TBL] [Abstract][Full Text] [Related]
17. Uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement: a case report of a diagnostic pitfall of uterine sarcoma.
Kubo T; Sugita S; Wada R; Kikuchi N; Iwasaki M; Ito Y; Sugawara T; Fujita H; Emori M; Tanaka R; Hirano H; Saito T; Hasegawa T
Diagn Pathol; 2017 Mar; 12(1):26. PubMed ID: 28288693
[TBL] [Abstract][Full Text] [Related]
18. DOG1 immunoreactivity in uterine leiomyosarcomas.
Sah SP; McCluggage WG
J Clin Pathol; 2013 Jan; 66(1):40-3. PubMed ID: 23038686
[TBL] [Abstract][Full Text] [Related]
19. KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature.
Zafrakas M; Theodoridis TD; Zepiridis L; Venizelos ID; Agorastos T; Bontis J
Eur J Gynaecol Oncol; 2008; 29(3):264-6. PubMed ID: 18592792
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours].
Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Le Frere Belda MA; Averous G; Leroux A; Bataillon G; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
Bull Cancer; 2024 Jan; 111(1):97-116. PubMed ID: 37806863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
